Quality of life in long-term survivors of the Hemopump left ventricular assist device.
The courses of 10 patients (nine men and one woman; mean age, 54 years) were reviewed to determine the long-term results of treatment with the Hemopump (Nimbus Medical, Inc., Rancho Cordova, CA) left ventricular assist device. Indications for treatment were postcardiotomy cardiogenic shock (n = 8) and acute cardiac allograft rejection (n = 2). Two of the patients with postcardiotomy shock required a bridge to transplantation. At follow-up (mean, 21 months), eight patients were alive: four were in New York Heart Association Functional Class I and four were in Class II. None had long-term adverse effects that were attributable to the site of insertion (e.g., limb ischemia or infected groin wounds). All the patients considered themselves independent in their daily activities, and most of the patients were able to exercise and pursue hobbies. The Hemopump appears to offer long-term survival with an acceptable quality of life to a population of patients whose survival would have been highly unlikely otherwise.
Baldwin
R T
RT
Cullen Cardiovascular Research Laboratories, Texas Heart Institute, Houston 77225-0345.
Radovancevic
B
B
Duncan
J M
JM
Ford
S
S
Lonquist
J L
JL
Munoz
E
E
Abou-Awdi
N L
NL
Frazier
O H
OH
D000203:Activities of Daily Living; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D016027:Heart Transplantation; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy; D011788:Quality of Life; D012770:Shock, Cardiogenic / Q000628:therapy*